Merus Stock (NASDAQ:MRUS), Trade Ideas

Merus

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

Analyst Color

Biotech

Equities

News

Health Care

Small Cap

Markets

Analyst Ratings

Trading Ideas

General

GMAB

MRUS

On Sunday night, AstraZeneca Plc (NASDAQ: AZN) presented the Phase 3 FLAURA2 results evaluating Tagrisso plus chemotherapy versus Tagrisso monotherapy as first-line treatment for patients 

AstraZeneca&#39;s Tagrisso-Chemo Combo Data In Lung Cancer Sets High Bar For Johnson &amp; Johnson&#39;s Cancer Drug: Analyst

Price Target

Reiteration

Analyst Boosts Merus Price Target As AACR Updates Meaningfully De-Risk Its Head &amp; Cancer Therapy

Penny Stocks

Intraday Update

Movers

ALLR

ANGN

AXLA

BBBY

BLBX

BLCM

CFRX

CJJD

CLSK

CNSP

CYTO

DBGI

DRMA

ERIC

EVAX

GMDA

GSMG

HTGM

KRBP

LIDR

NOTE

OBLG

PEAR

PHIO

PRST

PTPI

RIOT

RLAY

SABS

SBSW

SDIG

SLGG

TORO

Tempest Therapeutics, Inc. - Common Stock

TPST

TRVI

UIHC

WINT

Gainers


	Glory Star New Media Group Holdings Limited (NASDAQ: GSMG) shares jumped 122% to $1.07 after the company announced the signing of a $60 million strategic investment with two institutional investors at $2.48 per share.


Why Glory Star New Media Group Shares Are Trading Higher By 122%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Merus NV

Needham analyst Ami Fadia reiterates Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and maintains $66 price target.

Needham Reiterates Buy on Merus, Maintains $66 Price Target

<a href="https://www.globenewswire.com/Tracker?data=OS-OQLs4YCxBLYFOedaV1A9AcJgjVYBpge1AAdM7hgH5HXUZfVIMzkBw7GeFILErYfPyX55r0ZRKb4RoN7140Q==">Merus N.V.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics&#xAE; and Triclonics&#xAE;), today announced preclinical data on zenocutuzumab (Zeno) in cancer models with high neuregulin 1 (NRG1) expression were presented at the American Association of Cancer Research (AACR) Annual Meeting 2024. &nbsp;
"Exemplary of our approach to developing multispecific antibodies, Zeno was selected utilizing unbiased assays to allow biology to teach us which is the best potential Biclonics&#xAE;. Thereafter, we continue to learn more both preclinically and mechanistically, to identify where the molecule holds potential," said Cecile Geuijen, Chief Scientific Officer of Merus. "In this study, we examined the efficacy of Zeno in preclinical models expressing high NRG1 levels and found evidence of anti-tumor activity in multiple tumor types."
​Zenocutuzumab, a HER2 × HER3 bispecific antibody, is effective in cancer models with high NRG1 expression​ Observations in the presentation include:
<ul>
<li>Patient-derived xenograft (PDX) models (28 PDX models total) representing 21 different tumor types were selected based on high NRG1 expression in the respective tumor types</li>
<li>Zeno induced significant tumor growth inhibition in seven of the 28 PDX models tested</li>
<li>Zeno was also observed to:
<ul>
<li>Potently inhibit proliferation of N87 gastric cancer and SKBR-3 breast cancer cell lines at high NRG1 concentrations</li>
<li>Inhibit proliferation of HCC95, an NRG1-amplified lung cancer cell line, and block signaling through pathways involved in the regulation of cell growth and survival</li>
</ul>
</li>
<li>These data show that Zeno is effective in tumor cell killing in vitro and in vivo in high NRG1 expressing cancer models representing multiple different tumor types</li>
</ul>
The full presentation is available on the <a href="https://www.globenewswire.com/Tracker?data=WbR5YbHu98jMGHkstQH8bPQknbU5ShAxVJjyH1qCKADxf0WyrrUtTAyBUaJI92XFkwGpd1XlnEfW7ZzI5lLYBQIrgXxMqb7a94OUqJY20m7azpMGIEuYgDJ28OKbn5DM">Publications page</a> of our website.

Merus Presents Preclinical Data Demonstrating Efficacy Of Zeno In Cancer Models With High NRG1 Expression At The AACR Annual Meeting 2024

Truist Securities analyst Asthika Goonewardene initiates coverage on Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy rating and announces Price Target of $69.

Initiation

Truist Securities Initiates Coverage On Merus with Buy Rating, Announces Price Target of $69

Needham analyst Ami Fadia maintains Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and raises the price target from $65 to $66.

Needham Maintains Buy on Merus, Raises Price Target to $66

GILD

Gilead and Merus Announce Collaboration To Discover Novel Antibody-Based Trispecific T-Cell Engagers; Merus To Receive Upfront Cash Payment Of $56M For Initial Targets And Equity Investment By Gilead Of $25M in Merus Common Shares, Merus Is Also Eligible to Receive Up to $1.5B

Merus Announces Publication Of Abstract For Presentation At AACR Annual Meeting 2024

Needham analyst Ami Fadia maintains Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and raises the price target from $42 to $65.

Needham Maintains Buy on Merus, Raises Price Target to $65

Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(0.74) by 47.3 percent. This is a 39.78 percent increase over losses of $(1.81) per share from the same period last year. The company reported quarterly sales of $8.94 million which missed the analyst consensus estimate of $10.13 million by 11.76 percent. This is a 16.19 percent decrease over sales of $10.67 million the same period last year.

Earnings

On Wednesday February 28, 2024, Merus Reported Q4 Adjusted. EPS $(1.09) Misses $(0.74) Estimate, Sales $8.94M Miss $10.13M Estimate

HC Wainwright &amp; Co. analyst Andrew Fein maintains Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and raises the price target from $48 to $65.

HC Wainwright & Co. Maintains Buy on Merus, Raises Price Target to $65

Stifel analyst Bradley Canino maintains Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and raises the price target from $40 to $65.

Stifel Maintains Buy on Merus, Raises Price Target to $65

BMO Capital analyst Etzer Darout maintains Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Outperform and raises the price target from $49 to $58.

BMO Capital Maintains Outperform on Merus, Raises Price Target to $58

Cash Runway, existing cash, cash equivalents and marketable securities expected to fund Merus' operations into 2027 As of&nbsp;December 31, 2023, Merus had&nbsp;$411.7 million&nbsp;cash, cash equivalents and marketable securities. Based on the Company's current operating plan, the existing cash, cash equivalents and marketable securities are expected to fund Merus' operations into 2027.

As Of December 31, 2023, Merus Had $411.7M Cash, Cash Equivalents And Marketable Securities

Needham analyst Ami Fadia reiterates Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and maintains $42 price target.

Needham Reiterates Buy on Merus, Maintains $42 Price Target

Merus Presented Updated Clinical Data On MCLA-129 For Cancer Treatment At ESMO Asia 2023

Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) has observed the following analyst ratings within the last quarter: 
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
These 4 analysts have an average price target of $43.0 versus the current price of Merus at $24.21, implying upside.
Below is a summary of how these 4 analysts rated Merus over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock
<img src="https://www.benzinga.com/files/images/story/2023/1701172815_0.png" alt="price target chart" />
This current average represents a 4.44% decrease from the previous average price target of $45.00. 
<a href="https://www.benzinga.com/quote/MRUS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Merus analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h1>Analyst Ratings: What Are They?</h1>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Ratings for Merus

-&nbsp; Oral presentation on MCLA-129 in combination with osimertinib as first line therapy, and in previously treated, NSCLC on Sunday, December 3 at 9:40 a.m. SGT&nbsp; &nbsp;
-&nbsp; Poster presentation on MCLA-129 in previously treated HNSCC on Saturday, December 2 at 17:50 p.m. SGT &nbsp;
-&nbsp; Investor call on Monday, November 27, 2023 8:00 a.m. ET &nbsp;
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 26, 2023 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=kEXx0QVzz2jfnNFb2O1UkAl3Pcim3A1J8Tu_7ONAGzHpjN58gn2jiZK6wpTI6UQFwVe6R-A_1q-VNT5ElKcXkg==">Merus N.V.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics&#xAE; and Triclonics&#xAE;), today announced the publication of two abstracts regarding MCLA-129 on the European Society for Medical Oncology (ESMO) Asia Congress <a href="https://www.globenewswire.com/Tracker?data=p3i3RumdmrZfscxsY1Y7R8xp8g4eS3DHyQgAgnt-tu7zauS4w1eKRL3CT0swSkaaYSI_rTPXLNDkikOZd-iW_eNV22P_Cq6JS4vvNXhYYerYvjxZZEtrSZNEPYAPsFED">website.</a> The abstracts highlight updated interim clinical data from expansion cohorts in non-small cell lung cancer (NSCLC) and in previously treated head and neck squamous cell carcinoma (HNSCC) for presentation at the ESMO Asia Congress 2023 taking place in Singapore December 1-3, 2023.
"MCLA-129 is now the third asset, together with our other clinical assets petosemtamab and zenocutuzumab, developed from the Merus proprietary Biclonics&#xAE; platform to demonstrate strong clinical activity," said Bill Lundberg, M.D., President, Chief Executive Officer of Merus. "As we continue the development of MCLA-129, we are planning to take a disciplined capital allocation approach, making focused investments in the program to identify areas of potential differentiation. We remain open to potential business development opportunities as a means to leverage added resources, infrastructure and expertise of a potential partner to more fully evaluate and develop MCLA-129."
MCLA-129 (EGFR x c-MET Biclonics&#xAE;): Solid Tumors Interim data included in the abstracts describe data from three expansion cohorts in the open label trial evaluating MCLA-129 in combination with osimertinib, a third generation EGFR TKI, in treatment-naïve EGFR mutant (m) NSCLC and in EGFRm NSCLC that has progressed on osimertinib, as well as MCLA-129 monotherapy in previously treated HNSCC.
Updated clinical data, with additional patients and a later data cutoff date, will be included in the mini-oral presentation on NSCLC and the poster on HNSCC at ESMO Asia next week.
Mini-oral presentation title: Efficacy and safety of MCLA-129, an EGFR x c-MET bispecific antibody, combined with osimertinib, as first-line therapy or after progression on osimertinib in non-small cell lung cancer (NSCLC)&nbsp; Observations in the abstract include:&nbsp;&nbsp;
<ul>
<li>As of a May 10, 2023 data cutoff date, 48 patients (pts) with advanced/metastatic EGFRm NSCLC were treated (14/1L, 34/2L+)
<ul>
<li>In the 1L setting, 14 pts were treated, with 10 pts evaluable for response &nbsp;&nbsp;
<ul>
<li>2 confirmed partial responses (PRs) and 6 unconfirmed PRs were observed (8/10, 80%; 95% CI 44-98)&nbsp;by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. per investigator assessment; all responses were ongoing as of the data cutoff date</li>
<li>90% disease control rate (DCR) (95% CI 56-100)&nbsp;</li>
<li>10 weeks (range 2-26) median duration of exposure with 93% continuing treatment</li>
</ul>
</li>
<li>In the 2L+ setting, 34 pts were treated, with 22 pts evaluable for response
<ul>
<li>All received prior osimertinib in 1L/2L setting, 71% as the most recent therapy; 24% received prior chemotherapy</li>
<li>6 confirmed PRs and 5 unconfirmed PRs were observed (11/22, 50%; 95% CI 28-72) by RECIST v1.1. per investigator assessment; 9 responses were ongoing as of the data cutoff date, including 4 of the unconfirmed PRs</li>
<li>82% DCR (95% CI 60-95)</li>
<li>10 weeks (range 2-38) median duration of exposure with 68% continuing treatment&nbsp;</li>
</ul>
</li>
</ul>
</li>
<li>Early safety assessment in 48 NSCLC pts treated with MCLA-129 plus osimertinib included
<ul>
<li>Most common adverse events (AEs) regardless of causality were infusion related reactions (IRRs; composite term) in 85% (6% ≥ grade(G) 3)</li>
<li>Skin toxicity (composite term) in 75% (4% G3)</li>
<li>Treatment related interstitial lung disease (ILD)/pneumonitis in five patients (10%), two were G2, two were G3, and one was G5 and one progressed to G5 after the data cutoff date</li>
<li>Venous thromboembolic (VTE) events in 15%; 4% treatment related &nbsp;</li>
</ul>
</li>
</ul>
Presentation Details: Session: Thoracic Cancer Date: Sunday, December 3, 2023 Time: 9:40 -9:45 a.m. SGT Presentation #: 516MO
Poster presentation title: Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in head and neck squamous cell cancer (HNSCC)&nbsp; Observations in the abstract include:&nbsp;&nbsp;
<ul>
<li>As of a May 10, 2023 data cutoff date, 18 pts with previously treated HNSCC were treated
<ul>
<li>Pts received median of two lines prior therapy, 89% prior chemotherapy, 78% prior anti-PD-(L)1, 28% prior cetuximab</li>
<li>12 pts were evaluable for response &nbsp;&nbsp;
<ul>
<li>2 unconfirmed PRs were observed (2/12, 17%) by RECIST v1.1. per investigator assessment; one response was ongoing as of the data cutoff date&nbsp;&nbsp;</li>
<li>67% DCR (95% CI 35-90%)</li>
<li>8 weeks (range 2-17) median duration of exposure with 50% continuing on treatment</li>
</ul>
</li>
</ul>
</li>
<li>Early safety assessment in 18 HNSCC pts treated with MCLA-129 monotherapy included
<ul>
<li>Most common AEs regardless of causality were IRRs (composite term) in 72% (28% ≥ G3), all on cycle 1 day 1, that led to treatment discontinuation in two pts</li>
<li>Skin toxicity in 61% (11% G3)</li>
<li>No ILD or VTE events were reported</li>
</ul>
</li>
</ul>
Presentation details: Session Category: Poster session&nbsp; Date: Saturday, December 2, 2023&nbsp;&nbsp; Time: 17:50-18:45 p.m. SGT&nbsp; Presentation #: 362P&nbsp;
MCLA-129 Development Strategy In EGFRm NSCLC, with the strong clinical activity for MCLA-129 shown in the interim data presented today, we are encouraged by the potential for MCLA-129 in the treatment of lung cancer and beyond. We have identified focused investment opportunities. We continue to follow patients with EGFRm NSCLC treated with MCLA-129 in combination with osimertinib, to evaluate potential for biomarkers as a means to maximize efficacy, while proactively addressing safety signals seen to date.&nbsp;
We plan to start a cohort of MCLA-129 in combination with chemotherapy in 2L+ EGFRm NSCLC in the first quarter of next year.&nbsp;
Additionally, we remain interested and are continuing investigation of cohort B evaluating MCLA-129 in patients with MET exon14 skipping NSCLC. We also remain interested in exploring partnering MCLA-129 with other companies to sufficiently resource the development of MCLA-129 and potential benefit it may have for patients.
In HNSCC, based on the interim data, we observed clinical activity with MCLA-129. However, we view the clinical activity with MCLA-129 monotherapy as of the cutoff date as modest, with 2 unconfirmed partial responses or 17%. The safety profile was manageable, and there were no reported ILD or VTE events. Our assessment of this cohort is that the clinical activity of MCLA-129 in second line head and neck cancer appears substantially inferior to that of our lead asset petosemtamab, and only on par with other EGFR or cetuximab-based monoclonal or bispecific antibodies as monotherapy in a similar setting. We believe this efficacy is insufficient to warrant further development in head and neck cancer.
Zenocutuzumab (Zeno or MCLA-128: HER2 x HER3 Biclonics&#xAE;): NRG1 fusion (NRG1+) cancer and other solid tumors An abstract for an encore of a recent ESMO Congress 2023 presentation on zenocutuzumab interim clinical data from the eNRGy trial and Early Access Program in patients with NRG1 fusion (NRG1+) NSCLC has also been accepted for presentation at ESMO Asia. &nbsp;&nbsp;
Presentation details: Title:&nbsp;Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)&nbsp; Session Category: Poster session&nbsp; Date: Saturday, December 2, 2023&nbsp;&nbsp; Time: 17:50-18:45 p.m. SGT&nbsp; Presentation #: 595P&nbsp;
As full presentations become available at the ESMO Asia Congress 2023, they will contemporaneously be available on the Merus <a href="https://www.globenewswire.com/Tracker?data=p3i3RumdmrZfscxsY1Y7R47257w04-gS16vjuokO-UkuvH_uVpeuuAl97dykeQC8J8kToOfbTe8xndWDKteFzWSW4V9iHe7ACoYkbtmQhuk=">website</a>.&nbsp;
Company Conference Call and Webcast Information Merus will hold a conference call and webcast for investors on November 27, 2023 at 8:00 a.m. ET. A replay will be available after the completion of the call in the <a href="https://www.globenewswire.com/Tracker?data=93AT60wFdVft7rQo7NJYpdHCLjuqaFjEuXXO17NpGPmdk44MSakjGx9GUHS165gGKdBPpDI9iQhXYtP-0tKQruYSvIcV_37K3LCvXpVdx30j5DTj3jitbyAQWwaMi8znCKVS1_Sqosmyq62v2Xlt0h4YPbKhmEAd43ZTSQrvecSKbDxrBezpfBNrPd7IE4EW9xlNyKfCuA6SYI6OkYXRS20dSphYQGbAsqX2Mc9rKNoQ04u_xuC4nuI2MQdUV8I1O1sTcIdYmrJOe2Rbw21d_A==">Investors and Media</a> section of our website for a limited time.
Date and Time: November 27, 2023 at 8:00 a.m. ET Webcast link: Available on our website Dial-in: Toll-Free: 1 (800) 715-9871 / International: 1 (646) 307-1963 Conference ID: 2833671

Merus Announces Publication Of Abstracts On MCLA-129 For Presentation At ESMO Asia Congress 2023

Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.75) by 42.67 percent. This is a 18.87 percent increase over losses of $(0.53) per share from the same period last year. The company reported quarterly sales of $11.03 million which beat the analyst consensus estimate of $10.38 million by 6.29 percent. This is a 67.65 percent increase over sales of $6.58 million the same period last year.

Earnings Beats

Merus Q3 EPS $(0.43) Beats $(0.75) Estimate, Sales $11.03M Beat $10.38M Estimate

Canaccord Genuity analyst Bill Maughan initiates coverage on Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy rating and announces Price Target of $45.

Canaccord Genuity Initiates Coverage On Merus with Buy Rating, Announces Price Target of $45

Within the last quarter, Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) has observed the following analyst ratings: 
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the last 3 months, 8 analysts have offered 12-month price targets for Merus. The company has an average price target of $44.0 with a high of $48.00 and a low of $35.00. 
Below is a summary of how these 8 analysts rated Merus over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock
<img src="https://www.benzinga.com/files/images/story/2023/1698174025_0.png" alt="price target chart" />
This current average has decreased by 3.83% from the previous average price target of $45.75. 
<a href="https://www.benzinga.com/quote/MRUS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Merus analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h1>Analyst Ratings: What Are They?</h1>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Latest Analyst Ratings for Merus

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Merus (MRUS – Research Report), Stevanato Group (STV...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Big Pharma patent cliffs seen fueling oncology M&A this year

Cantor Fitzgerald sees strong year ahead for oncology M&A

Cantor sees strong year ahead for oncology M&A

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ocuphire Pharma (OCUP – Research Report), Merus (MRU...

Analysts Offer Insights on Healthcare Companies: Ocuphire Pharma (OCUP), Merus (MRUS) and Eli Lilly & Co (LLY)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Geron (GERN – Research Report), Merus (MRUS – Resear...

Analysts Offer Insights on Healthcare Companies: Geron (GERN), Merus (MRUS) and MoonLake Immunotherapeutics (MLTX)

The 98 rating InvestorsObserver gives to Merus NV (MRUS)  stock puts it near the top of the Healthcare sector.In addition to scoring higher than 90 percent of stocks in the Healthcare sector, MRUSâ€&#x2122;s 98 overall rating means the stock scores better than 98 of all stocks. MRUS has an Overall Score of 98. Find out what this me

Should You Add Merus NV (MRUS) Stock to Your Portfolio Monday?

Merus NV (MRUS) is around the top of the Biotechnology industry according to InvestorsObserver. MRUS received an overall rating of 72, which means that it scores higher than 72 percent of all stocks. Merus NV also achieved a score of 87 in the Biotechnology industry, putting it above 87 percent of Biotechnology stocks. Bio

Is Merus NV (MRUS) a Smart Choice in Biotechnology Monday?

Merus NV (MRUS) is around the top of the Healthcare sector according to InvestorsObserver.MRUS received an overall rating of 84, which means that it scores higher than 84% of stocks. Additionally, Merus NV scored a 88 in the Healthcare sector, ranking it higher than 88% of stocks in that sector. MRUS has an Overall Score o

Should You Add Merus NV (MRUS) Stock to Your Portfolio Thursday?

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on ZimVie Inc (ZIMV – Research Report) and Merus (MRU...

Analysts Have Conflicting Sentiments on These Healthcare Companies: ZimVie Inc (ZIMV) and Merus (MRUS)

ALXO

AMAM

ARVN

BCYC

CGON

DAWN

DCPH

ERAS

EXEL

FUSN

GERN

HARP

IDYA

IMCR

IMTX

JANX

KPTI

KURA

LEGN

MLTX

NUVL

OCUP

OLMA

ORIC

PMVP

RVMD

SNDX

STVN

SWTX

URGN

VSTM

ZIMV

ZNTL

Press Releases

Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023

Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023

Merus to Participate in Upcoming Investor Conferences

Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update

Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference

Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression

Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers

Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024

Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting